Acute Ischemic Stroke Therapy Overview

Circulation Research

Volumn 120, Issue 3, 2017, Pages 541-558

  Catanese, Luciana ^a   Tarsia, Joseph ^a   Fisher, Marc ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

imaging; intervention; stroke; therapy; thrombolysis

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

APPARENT DIFFUSION COEFFICIENT; BRAIN ANGIOGRAPHY; BRAIN ISCHEMIA; BRAIN SCINTISCANNING; CLINICAL PRACTICE; COLLATERAL CIRCULATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG APPROVAL; ENDOVASCULAR SURGERY; FIBRINOLYSIS; FLUID ATTENUATED INVERSION RECOVERY; FOOD AND DRUG ADMINISTRATION; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT RETRIEVER; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; FIBRINOLYTIC THERAPY; PROCEDURES; STROKE; TREATMENT OUTCOME;

BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; ENDOVASCULAR PROCEDURES; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 85011915249     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.309278     Document Type: Review

References (138)

1. Mozaffarian D, Benjamin EJ, Go AS, How well does ASPECTS pre-dict. Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133:447-454. doi: 10.1161/CIR.0000000000000366.
2. Kissela BM, Khoury JC, Alwell K, Moomaw CJ, Woo D, Adeoye O, Flaherty ML, Khatri P, Ferioli S, De Los Rios La Rosa F, Broderick JP, Kleindorfer DO. Age at stroke: temporal trends in stroke incidence in a large, biracial population. Neurology. 2012;79:1781-1787. doi: 10.1212/WNL.0b013e318270401d.
3. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al.; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: fndings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-254.
4. Koton S, Schneider AL, Rosamond WD, Shahar E, Sang Y, Gottesman RF, Coresh J. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA. 2014;312:259-268. doi: 10.1001/jama.2014.7692.
5. Towfghi A, Saver JL, Engelhardt R, Ovbiagele B. A midlife stroke surge among women in the United States. Neurology. 2007;69:1898-1904. doi: 10.1212/01.wnl.0000268491.89956.c2.
6. Puyal J, Ginet V, Clarke PG. Multiple interacting cell death mechanisms in the mediation of excitotoxicity and ischemic brain damage: a challenge for neuroprotection. Prog Neurobiol. 2013;105:24-48. doi: 10.1016/j. pneurobio.2013.03.002.
7. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67:181-198. doi: 10.1016/j. neuron.2010.07.002.
8. Bardutzky J, Shen Q, Henninger N, Bouley J, Duong TQ, Fisher M. Differences in ischemic lesion evolution in different rat strains using diffusion and perfusion imaging. Stroke. 2005;36:2000-2005. doi: 10.1161/01. STR.0000177486.85508.4d.
9. Fisher M, Bastan B. Identifying and utilizing the ischemic penumbra. Neurology. 2012;79:S79-S85. doi: 10.1212/WNL.0b013e3182695814.
10. Fisher M, Albers GW. Advanced imaging to extend the therapeutic time window of acute ischemic stroke. Ann Neurol. 2013;73:4-9. doi: 10.1002/ana.23744.
11. Heiss WD. The ischemic penumbra: how does tissue injury evolve? Ann N Y Acad Sci. 2012;1268:26-34. doi: 10.1111/j.1749-6632.2012.06668.x.
12. Wardlaw JM, Mielke O. Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment-systematic review. Radiology. 2005;235:444-453. doi: 10.1148/radiol.2352040262.
13. von Kummer R, Bourquain H, Bastianello S, Bozzao L, Manelfe C, Meier D, Hacke W. Early prediction of irreversible brain damage after ischemic stroke at CT. Radiology. 2001;219:95-100. doi: 10.1148/radiology.219.1.r01ap0695.
14. Butcher KS, Lee SB, Parsons MW, Allport L, Fink J, Tress B, Donnan G, Davis SM; EPITHET Investigators. Differential prognosis of isolated cortical swelling and hypoattenuation on CT in acute stroke. Stroke. 2007;38:941-947. doi: 10.1161/01.STR.0000258099.69995.b6.
15. Lev MH, Farkas J, Gemmete JJ, Hossain ST, Hunter GJ, Koroshetz WJ, Gonzalez RG. Acute stroke: improved nonenhanced CT detection-bene-fts of soft-copy interpretation by using variable window width and center level settings. Radiology. 1999;213:150-155. doi: 10.1148/radiology.213. 1.r99oc10150.
16. Barber PA, Hill MD, Eliasziw M, Demchuk AM, Pexman JH, Hudon ME, Tomanek A, Frayne R, Buchan AM; ASPECTS Study Group. Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry. 2005;76:1528-1533. doi: 10.1136/jnnp.2004.059261.
17. Puetz V, Dzialowski I, Hill MD, Demchuk AM. The Alberta Stroke Program Early CT Score in clinical practice: what have we learned? Int J Stroke. 2009;4:354-364. doi: 10.1111/j.1747-4949.2009.00337.x.
18. Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabín J; CLOTBUST Investigators. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke. 2004;35:151-156. doi: 10.1161/01. STR.0000106485.04500.4A.
19. Weir NU, Pexman JH, Hill MD, Buchan AM; CASES Investigators. How well does ASPECTS predict the outcome of acute stroke treated with IV tPA? Neurology. 2006;67:516-518. doi: 10.1212/01. wnl.0000228221.44334.73.
20. Demchuk AM, Hill MD, Barber PA, Silver B, Patel SC, Levine SR; NINDS rtPA Stroke Study Group, NIH. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. Stroke. 2005;36:2110-2115. doi: 10.1161/01.STR.0000181116.15426.58.
21. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientifc Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016;47:581-641. doi: 10.1161/STR.0000000000000086.
22. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfeld K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947. doi: 10.1161/STR.0b013e318284056a.
23. Berkhemer OA, Fransen PS, Beumer D, et al-; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11-20. doi: 10.1056/NEJMoa1411587.
24. Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, Johnston KC, Johnston SC, Khalessi AA, Kidwell CS, Meschia JF, Ovbiagele B, Yavagal DR; American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46:3020-3035. doi: 10.1161/STR.0000000000000074.
25. Badhiwala JH, Nassiri F, Alhazzani W, et al. Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis. JAMA. 2015;314:1832-1843. doi: 10.1001/jama.2015.13767.
26. Lindsberg PJ ST, Nagel S, Salonen O, Silvennoinen H, Stribian D. Recanalization treatments in basilar artery occlusion-Systematic analy-sis. 2016;1:41-60.
27. Bastianello S, Pierallini A, Colonnese C, Brughitta G, Angeloni U, Antonelli M, Fantozzi LM, Fieschi C, Bozzao L. Hyperdense middle cerebral artery CT sign. Comparison with angiography in the acute phase of ischemic supratentorial infarction. Neuroradiology. 1991;33:207-211.
28. von Kummer R, Meyding-Lamadé U, Forsting M, Rosin L, Rieke K, Hacke W, Sartor K. Sensitivity and prognostic value of early CT in oc-clusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol. 1994;15:9-15; discussion 16.
29. Tomsick T, Brott T, Barsan W, Broderick J, Haley EC, Spilker J. Thrombus localization with emergency cerebral CT. AJNR Am J Neuroradiol. 1992;13:257-263.
30. Leary MC, Kidwell CS, Villablanca JP, et al. Validation of computed tomo-graphic middle cerebral artery "dot"sign: an angiographic correlation study. Stroke. 2003;34:2636-2640. doi: 10.1161/01.STR.0000092123.00938.83.
31. Ozdemir O, Leung A, Bussiére M, Hachinski V, Pelz D. Hyperdense internal carotid artery sign: a CT sign of acute ischemia. Stroke. 2008;39:2011-2016. doi: 10.1161/STROKEAHA.107.505230.
32. Jensen UR, Weiss M, Zimmermann P, Jansen O, Riedel C. The hyperdense anterior cerebral artery sign (HACAS) as a computed tomography marker for acute ischemia in the anterior cerebral artery territory. Cerebrovasc Dis. 2010;29:62-67. doi: 10.1159/000256648.
33. Krings T, Noelchen D, Mull M, Willmes K, Meister IG, Reinacher P, Toepper R, Thron AK. The hyperdense posterior cerebral artery sign: a computed tomography marker of acute ischemia in the posterior cerebral artery territory. Stroke. 2006;37:399-403. doi: 10.1161/01. STR.0000199062.09010.77.
34. Goldmakher GV, Camargo EC, Furie KL, Singhal AB, Roccatagliata L, Halpern EF, Chou MJ, Biagini T, Smith WS, Harris GJ, Dillon WP, Gonzalez RG, Koroshetz WJ, Lev MH. Hyperdense basilar artery sign on unenhanced CT predicts thrombus and outcome in acute posterior circulation stroke. Stroke. 2009;40:134-139. doi: 10.1161/STROKEAHA.108.516690.
35. Nguyen-Huynh MN, Wintermark M, English J, Lam J, Vittinghoff E, Smith WS, Johnston SC. How accurate is CT angiography in evaluating intracranial atherosclerotic disease? Stroke. 2008;39:1184-1188. doi: 10.1161/STROKEAHA.107.502906.
36. Lev MH, Farkas J, Rodriguez VR, Schwamm LH, Hunter GJ, Putman CM, Rordorf GA, Buonanno FS, Budzik R, Koroshetz WJ, Gonzalez RG. CT angiography in the rapid triage of patients with hyperacute stroke to intra-arterial thrombolysis: accuracy in the detection of large vessel thrombus. J Comput Assist Tomogr. 2001;25:520-528.
37. Puetz V, Dzialowski I, Coutts SB, Hill MD, Krol A, O'Reilly C, Goyal M, Demchuk AM; Calgary CTA Study Group. Frequency and clinical course of stroke and transient ischemic attack patients with intracranial nonocclusive thrombus on computed tomographic angiography. Stroke. 2009;40:193-199. doi: 10.1161/STROKEAHA.108.526277.
38. Tan IY, Demchuk AM, Hopyan J, Zhang L, Gladstone D, Wong K, Martin M, Symons SP, Fox AJ, Aviv RI. CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. AJNR Am J Neuroradiol. 2009;30:525-531. doi: 10.3174/ajnr.A1408.
39. Fanou EM, Knight J, Aviv RI, Hojjat SP, Symons SP, Zhang L, Wintermark M. Effect of collaterals on clinical presentation, baseline imaging, complications, and outcome in acute stroke. AJNR Am J Neuroradiol. 2015;36:2285-2291. doi: 10.3174/ajnr.A4453.
40. Puetz V, Dzialowski I, Hill MD, Subramaniam S, Sylaja PN, Krol A, O'Reilly C, Hudon ME, Hu WY, Coutts SB, Barber PA, Watson T, Roy J, Demchuk AM; Calgary CTA Study Group. Intracranial thrombus extent predicts clinical outcome, fnal infarct size and hemorrhagic transformation in ischemic stroke: the clot burden score. Int J Stroke. 2008;3:230-236. doi: 10.1111/j.1747-4949.2008.00221.x.
41. Campbell BC, Christensen S, Tress BM, Churilov L, Desmond PM, Parsons MW, Barber PA, Levi CR, Bladin C, Donnan GA, Davis SM; EPITHET Investigators. Failure of collateral blood fow is associated with infarct growth in ischemic stroke. J Cereb Blood Flow Metab. 2013;33:1168-1172. doi: 10.1038/jcbfm.2013.77.
42. Menon BK, Smith EE, Modi J, Patel SK, Bhatia R, Watson TW, Hill MD, Demchuk AM, Goyal M. Regional leptomeningeal score on CT angiogra-phy predicts clinical and imaging outcomes in patients with acute anterior circulation occlusions. AJNR Am J Neuroradiol. 2011;32:1640-1645. doi: 10.3174/ajnr.A2564.
43. Menon BK, d'Esterre CD, Qazi EM, Almekhlaf M, Hahn L, Demchuk AM, Goyal M. Multiphase CT angiography: a new tool for the imaging triage of patients with acute ischemic stroke. Radiology. 2015;275:510-520. doi: 10.1148/radiol.15142256.
44. Goyal M, Demchuk AM, Menon BK, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of isch-emic stroke. N Engl J Med. 2015;372:1019-1030. doi: 10.1056/NEJMoa1414905.
45. Frölich AM, Wolff SL, Psychogios MN, Klotz E, Schramm R, Wasser K, Knauth M, Schramm P. Time-resolved assessment of collateral fow using 4D CT angiography in large-vessel occlusion stroke. Eur Radiol. 2014;24:390-396. doi: 10.1007/s00330-013-3024-6.
46. Camargo EC, Furie KL, Singhal AB, Roccatagliata L, Cunnane ME, Halpern EF, Harris GJ, Smith WS, Gonzalez RG, Koroshetz WJ, Lev MH. Acute brain infarct: detection and delineation with CT angiographic source images versus nonenhanced CT scans. Radiology. 2007;244:541-548. doi: 10.1148/radiol.2442061028.
47. Coutts SB, Lev MH, Eliasziw M, Roccatagliata L, Hill MD, Schwamm LH, Pexman JH, Koroshetz WJ, Hudon ME, Buchan AM, Gonzalez RG, Demchuk AM. ASPECTS on CTA source images versus unenhanced CT: added value in predicting fnal infarct extent and clinical outcome. Stroke. 2004;35:2472-2476. doi: 10.1161/01.STR.0000145330. 14928.2a.
48. Schramm P, Schellinger PD, Klotz E, Kallenberg K, Fiebach JB, Külkens S, Heiland S, Knauth M, Sartor K. Comparison of perfusion computed tomography and computed tomography angiography source images with perfusion-weighted imaging and diffusion-weighted imaging in patients with acute stroke of less than 6 hours' duration. Stroke. 2004;35:1652-1658. doi: 10.1161/01.STR.0000131271.54098.22.
49. Puetz V, Khomenko A, Hill MD, et al; Basilar Artery International Cooperation Study (BASICS) Group. Extent of hypoattenuation on CT angiography source images in basilar artery occlusion: prognostic value in the Basilar Artery International Cooperation Study. Stroke. 2011;42:3454-3459. doi: 10.1161/STROKEAHA.111.622175.
50. Lev MH, Romero JM, Goodman DN, Bagga R, Kim HY, Clerk NA, Ackerman RH, Gonzalez RG. Total occlusion versus hairline residual lu-men of the internal carotid arteries: accuracy of single section helical CT angiography. AJNR Am J Neuroradiol. 2003;24:1123-1129.
51. González RG, Schaefer PW, Buonanno FS, Schwamm LH, Budzik RF, Rordorf G, Wang B, Sorensen AG, Koroshetz WJ. Diffusion-weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset. Radiology. 1999;210:155-162. doi: 10.1148/radiology.21 0.1.r99ja02155.
52. Schellinger PD, Bryan RN, Caplan LR, Detre JA, Edelman RR, Jaigobin C, Kidwell CS, Mohr JP, Sloan M, Sorensen AG, Warach S; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence-based guideline: The role of diffusion and per-fusion MRI for the diagnosis of acute ischemic stroke: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;75:177-185. doi: 10.1212/WNL.0b013e3181e7c9dd.
53. Kidwell CS, Saver JL, Mattiello J, Starkman S, Vinuela F, Duckwiler G, Gobin YP, Jahan R, Vespa P, Kalafut M, Alger JR. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol. 2000;47:462-469.
54. Purushotham A, Campbell BC, Straka M, Mlynash M, Olivot JM, Bammer R, Kemp SM, Albers GW, Lansberg MG. Apparent diffusion coeffcient threshold for delineation of ischemic core. Int J Stroke. 2015;10:348-353. doi: 10.1111/ijs.12068.
55. Sanossian N, Saver JL, Alger JR, Kim D, Duckwiler GR, Jahan R, Vinuela F, Ovbiagele B, Liebeskind DS. Angiography reveals that fuid-attenuat-ed inversion recovery vascular hyperintensities are due to slow fow, not thrombus. AJNR Am J Neuroradiol. 2009;30:564-568. doi: 10.3174/ajnr. A1388.
56. Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke. 2004;35:2659-2661. doi: 10.1161/01.STR.0000144051.32131.09.
57. Tsivgoulis G, Zand R, Katsanos AH, et al. Risk of symptomatic intrace-rebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden: a meta-analysis. JAMA Neurol. 2016;73:675-683. doi: 10.1001/jamaneurol.2016.0292.
58. Provenzale JM, Sarikaya B. Comparison of test performance characteristics of MRI, MR angiography, and CT angiography in the diagnosis of carotid and vertebral artery dissection: a review of the medical literature. AJR Am J Roentgenol. 2009;193:1167-1174. doi: 10.2214/AJR.08.1688.
59. Cuvinciuc V, Viallon M, Momjian-Mayor I, Sztajzel R, Pereira VM, Lovblad KO, Vargas MI. 3D fat-saturated T1 SPACE sequence for the diagnosis of cervical artery dissection. Neuroradiology. 2013;55:595-602. doi: 10.1007/s00234-013-1141-1.
60. Bash S, Villablanca JP, Jahan R, Duckwiler G, Tillis M, Kidwell C, Saver J, Sayre J. Intracranial vascular stenosis and occlusive disease: evaluation with CT angiography, MR angiography, and digital subtraction angiogra-phy. AJNR Am J Neuroradiol. 2005;26:1012-1021.
61. Serfaty JM, Chirossel P, Chevallier JM, Ecochard R, Froment JC, Douek PC. Accuracy of three-dimensional gadolinium-enhanced MR angiogra-phy in the assessment of extracranial carotid artery disease. AJR Am J Roentgenol. 2000;175:455-463. doi: 10.2214/ajr.175.2.1750455.
62. Lin L, Bivard A, Parsons MW. Perfusion patterns of ischemic stroke on computed tomography perfusion. J Stroke. 2013;15:164-173. doi: 10.5853/jos.2013.15.3.164.
63. Bivard A, Levi C, Spratt N, Parsons M. Perfusion CT in acute stroke: a comprehensive analysis of infarct and penumbra. Radiology. 2013;267:543-550. doi: 10.1148/radiol.12120971.
64. Campbell BC, Christensen S, Levi CR, Desmond PM, Donnan GA, Davis SM, Parsons MW. Comparison of computed tomogra-phy perfusion and magnetic resonance imaging perfusion-diffusion mismatch in ischemic stroke. Stroke. 2012;43:2648-2653. doi: 10.1161/STROKEAHA.112.660548.
65. Mlynash M, Lansberg MG, De Silva DA, Lee J, Christensen S, Straka M, Campbell BC, Bammer R, Olivot JM, Desmond P, Donnan GA, Davis SM, Albers GW; DEFUSE-EPITHET Investigators. Refning the defnition of the malignant profle: insights from the DEFUSE-EPITHET pooled data set. Stroke. 2011;42:1270-1275. doi: 10.1161/STROKEAHA. 110.601609.
66. Saver JL. Time is brain-quantifed. Stroke. 2006;37:263-266. doi: 10.1161/01.STR.0000196957.55928.ab.
67. Sussman BJ, Fitch TS. Thrombolysis with fbrinolysin in cerebral arterial occlusion. J Am Med Assoc. 1958;167:1705-1709.
68. Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
69. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
70. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, Torner JC, Marler JR. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992;23:641-645.
71. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019-2026.
72. Davis SM, Donnan GA, Parsons MW, et al; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299-309. doi: 10.1016/S1474-4422(08)70044-9.
73. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with re-combinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274 1017-1025.
74. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombo-lytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
75. Hacke W, Donnan G, Fleschi C, et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
76. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329. doi: 10.1056/NEJMoa0804656.
77. Lees KR, Bluhmki E, von Kummer R, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703. doi: 10.1016/S0140-6736(10)60491-6.
78. IST-3 Collaborative Group; Sandercock P, Wardlaw JM, Lindley RI, et al. The benefts and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379:2352-2363. doi: 10.1016/S0140-6736(12)60768-5.
79. del Río-Espínola A, Fernández-Cadenas I, Giralt D, et al; GRECOS Investigators. A predictive clinical-genetic model of tissue plasminogen activator response in acute ischemic stroke. Ann Neurol. 2012;72:716-729. doi: 10.1002/ana.23664.
80. Fernández-Cadenas I, Del Río-Espínola A, Giralt D, Domingues-Montanari S, Quiroga A, Mendióroz M, Ruíz A, Ribó M, Serena J, Obach V, Freijo MM, Martí-Fábregas J, Delgado P, Montaner J. IL1B and VWF variants are associated with fbrinolytic early recanalization in patients with ischemic stroke. Stroke. 2012;43:2659-2665. doi: 10.1161/STROKEAHA.112.657007.
81. Mehta RH, Cox M, Smith EE, Xian Y, Bhatt DL, Fonarow GC, Peterson ED; Get With The Guidelines-Stroke Program. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Stroke. 2014;45:2263-2269. doi: 10.1161/STROKEAHA.114.005019.
82. Savitz SI, Schlaug G, Caplan L, Selim M. Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke. Stroke. 2005;36:1447-1451. doi: 10.1161/01.STR.0000170647.42126.a8.
83. Masrur S, Cox M, Bhatt DL, Smith EE, Ellrodt G, Fonarow GC, Schwamm L. Association of acute and chronic hyperglycemia with acute ischemic stroke outcomes post-thrombolysis: fndings from Get With The Guidelines-Stroke. J Am Heart Assoc. 2015;4:e002193. doi: 10.1161/JAHA.115.002193.
84. Abboud H, Labreuche J, Plouin F, Amarenco P; GENIC Investigators. High blood pressure in early acute stroke: a sign of a poor outcome? J Hypertens. 2006;24:381-386. doi: 10.1097/01.hjh.0000200516.33194.e3.
85. Bhatia R, Hill MD, Shobha N, Menon B, Bal S, Kochar P, Watson T, Goyal M, Demchuk AM. Low rates of acute recanalization with intravenous re-combinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010;41:2254-2258. doi: 10.1161/STROKEAHA.110.592535.
86. Van De Werf F, Adgey J, Ardissino D, et al. Single bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet. 1999;354:716-722.
87. Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, Levine SR, Johnston KC, Buchsbaum R, Levy G, Levin B; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41:707-711. doi: 10.1161/STROKEAHA.109.572040.
88. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099-1107. doi: 10.1056/NEJMoa1109842.
89. Parsons MW, Miteff F, Bateman GA, Spratt N, Loiselle A, Attia J, Levi CR. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology. 2009;72:915-921. doi: 10.1212/01. wnl.0000344168.05315.9d.
90. Parsons M. Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12613000243718. Accessed June 15, 2016.
91. Logallo N, Kvistad CE, Nacu A, Naess H, Waje-Andreassen U, Asmuss J, Aamodt AH, Lund C, Kurz MW, Rønning OM, Salvesen R, Idicula TT, Thomassen L. The Norwegian tenecteplase stroke trial (NOR-TEST): ran-domised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol. 2014;14:106. doi: 10.1186/1471-2377-14-106.
92. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73. doi: 10.1161/01. STR.0000149938.08731.2c.
93. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W; DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and effcacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231. doi: 10.1161/01.STR.0000217403.66996.6d.
94. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in pa-tients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8:141-150. doi: 10.1016/S1474-4422(08)70267-9.
95. Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Grønning BA, Chabriat H, Chang KC, Davalos AE, Ford GA, Grotta J, Kaste M, Schwamm LH, Shuaib A; DIAS-3 Investigators. Safety and effcacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol. 2015;14:575-584. doi: 10.1016/S1474-4422(15)00047-2.
96. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29:4-11.
97. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
98. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, Lutsep HL, Nesbit GM, Grobelny T, Rymer MM, Silverman IE, Higashida RT, Budzik RF, Marks MP; MERCI Trial Investigators. Safety and effcacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke. 2005;36:1432-1438. doi: 10.1161/01. STR.0000171066.25248.1d.
99. Smith WS, Sung G, Saver J, et al; Multi MERCI Investigators. Mechanical thrombectomy for acute ischemic stroke: fnal results of the Multi MERCI trial. Stroke. 2008;39:1205-1212. doi: 10.1161/STROKEAHA.107.497115.
100. Penumbra Pivotal Stroke Trial, Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009;40:2761-2768. doi: 10.1161/STROKEAHA.108.544957.
101. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, Clark W, Budzik R, Zaidat OO; SWIFT Trialists. Solitaire fow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012;380:1241-1249. doi: 10.1016/S0140-6736(12)61384-1.
102. Pereira VM, Gralla J, Davalos A, et al. Prospective, multicenter, single-arm study of mechanical thrombectomy using Solitaire Flow Restoration in acute ischemic stroke. Stroke. 2013;44:2802-2807. doi: 10.1161/STROKEAHA.113.001232.
103. Jansen O, Macho JM, Killer-Oberpfalzer M, Liebeskind D, Wahlgren N; TREVO Study Group. Neurothrombectomy for the treatment of acute ischemic stroke: results from the TREVO study. Cerebrovasc Dis. 2013;36:218-225. doi: 10.1159/000353990.
104. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, Liebeskind DS, Smith WS; TREVO 2 Trialists. Trevo versus Merci re-trievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012;380:1231-1240. doi: 10.1016/S0140-6736(12)61299-9.
105. Zaidat OO, Castonguay AC, Gupta R, et al. North American Solitaire Stent Retriever Acute Stroke registry: post-marketing revascularization and clinical outcome results. J Neurointerv Surg. 2014;6:584-588. doi: 10.1136/neurintsurg-2013-010895.
106. Pierot L, Soize S, Benaissa A, Wakhloo AK. Techniques for endo-vascular treatment of acute ischemic stroke: from intra-arterial fbri-nolytics to stent-retrievers. Stroke. 2015;46:909-914. doi: 10.1161/STROKEAHA.114.007935.
107. Kidwell CS, Jahan R, Gornbein J, et al; MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368:914-923. doi: 10.1056/NEJMoa1212793.
108. Jovin TG, Chamorro A, Cobo E, et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296-2306. doi: 10.1056/NEJMoa1503780.
109. Campbell BC, Mitchell PJ, Kleinig TJ, et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selec-tion. N Engl J Med. 2015;372:1009-1018. doi: 10.1056/NEJMoa1414792.
110. Saver JL, Goyal M, Bonafe A, et al; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372:2285-2295. doi: 10.1056/NEJMoa1415061.
111. Goyal M, Menon BK, van Zwam WH, et al; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from fve randomised trials. Lancet. 2016;387:1723-1731. doi: 10.1016/S0140-6736(16)00163-X.
112. Bracard S, Guillemin F, Ducrocq X. THRACE study: intermediate analy-sis results. Int J Stroke 2015:31.
113. Mocco J, Zaidat O, von Kummer R. Results of the THERAPY trial: a prospective, randomized trial to defne the role of mechanical thrombec-tomy as adjunctive treatment to IV rtPA in acute ischemic stroke. Int J Stroke. 2015;10:10.
114. Meyers PM, Schumacher HC, Connolly ES Jr, Heyer EJ, Gray WA, Higashida RT. Current status of endovascular stroke treatment. Circulation. 2011;123:2591-2601. doi: 10.1161/CIRCULATIONAHA.110.971564.
115. Thomalla G, Gerloff C. Treatment concepts for wake-up stroke and stroke with unknown time of symptom onset. Stroke. 2015;46:2707-2713. doi: 10.1161/STROKEAHA.115.009701.
116. Lansberg MG, Straka M, Kemp S, et al.; DEFUSE 2 study investigators. MRI profle and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol. 2012;11:860-867. doi: 10.1016/S1474-4422(12)70203-X.
117. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP; DEFUSE Investigators. Magnetic resonance imaging profles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60:508-517. doi: 10.1002/ana.20976.
118. Stroke Unit Trialists Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev. 2013:CD000197.
119. Gupta R, Horev A, Nguyen T, et al. Higher volume endovascular stroke centers have faster times to treatment, higher reperfusion rates and higher rates of good clinical outcomes. J Neurointerv Surg. 2013;5:294-297. doi: 10.1136/neurintsurg-2011-010245.
120. Southerland AM, Johnston KC, Molina CA, Selim MH, Kamal N, Goyal M. Suspected large vessel occlusion: should Emergency Medical Services transport to the nearest Primary Stroke Center or bypass to a Comprehensive Stroke Center with endovascular capabilities? Stroke. 2016;47:1965-1967. doi: 10.1161/STROKEAHA.115.011149.
121. Purrucker JC, Hametner C, Engelbrecht A, Bruckner T, Popp E, Poli S. Comparison of stroke recognition and stroke severity scores for stroke detection in a single cohort. J Neurol Neurosurg Psychiatry. 2015;86:1021-1028. doi: 10.1136/jnnp-2014-309260.
122. Silva GS, Farrell S, Shandra E, Viswanathan A, Schwamm LH. The status of telestroke in the United States: a survey of currently active stroke telemedicine programs. Stroke. 2012;43:2078-2085. doi: 10.1161/STROKEAHA.111.645861.
123. Bowry R, Parker S, Rajan SS, Yamal JM, Wu TC, Richardson L, Noser E, Persse D, Jackson K, Grotta JC. Benefts of stroke treatment using a mobile stroke unit compared with standard management: The BEST-MSU Study Run-In Phase. Stroke. 2015;46:3370-3374. doi: 10.1161/STROKEAHA.115.011093.
124. Goyal M, Yu AY, Menon BK, et al. Endovascular therapy in acute isch-emic stroke: challenges and transition from trials to bedside. Stroke. 2016;47:548-553. doi: 10.1161/STROKEAHA.115.011426.
125. Demchuk AM, Menon BK, Goyal M. Comparing vessel imaging: non-contrast computed tomography/computed tomographic angiography should be the new minimum standard in acute disabling stroke. Stroke. 2016;47:273-281. doi: 10.1161/STROKEAHA.115.009171.
126. Goyal M, Hill MD, Saver JL, Fisher M. Challenges and opportunities of endovascular stroke therapy. Ann Neurol. 2016;79:11-17. doi: 10.1002/ana.24528.
127. Ma H, Campbell BC, Parsons MW. Extending the time window for thrombolysis in emergency neurological defcits (EXTEND): high prevalence of intracranial vessel occlusion in wake-up stroke patients. Stroke. 2016;47:A59.
128. Fisher M, Saver JL. Future directions of acute ischaemic stroke therapy. Lancet Neurol. 2015;14:758-767. doi: 10.1016/S1474-4422(15)00054-X.
129. Henninger N, Bratane BT, Bastan B, Bouley J, Fisher M. Normobaric hy-peroxia and delayed tPA treatment in a rat embolic stroke model. J Cereb Blood Flow Metab. 2009;29:119-129. doi: 10.1038/jcbfm.2008.104.
130. Saver JL, Starkman S, Eckstein M, Stratton SJ, Pratt FD, Hamilton S, Conwit R, Liebeskind DS, Sung G, Kramer I, Moreau G, Goldweber R, Sanossian N; FAST-MAG Investigators and Coordinators. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med. 2015;372:528-536. doi: 10.1056/NEJMoa1408827.
131. Bråtane BT, Cui H, Cook DJ, Bouley J, Tymianski M, Fisher M. Neuroprotection by freezing ischemic penumbra evolution with-out cerebral blood fow augmentation with a postsynaptic den-sity-95 protein inhibitor. Stroke. 2011;42:3265-3270. doi: 10.1161/STROKEAHA.111.618801.
132. Hougaard KD, Hjort N, Zeidler D, et al. Remote ischemic percondition-ing as an adjunct therapy to thrombolysis in patients with acute isch-emic stroke: a randomized trial. Stroke. 2014;45:159-167. doi: 10.1161/STROKEAHA.113.001346.
133. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123:92-100. doi: 10.1172/JCI62874.
134. Sanderson TH, Reynolds CA, Kumar R, Przyklenk K, Hüttemann M. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxy-gen species generation. Mol Neurobiol. 2013;47:9-23. doi: 10.1007/s12035-012-8344-z.
135. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808. doi: 10.1038/nm.2399.
136. Ribo M, Flores A, Rubiera M, Pagola J, Sargento-Freitas J, Rodriguez-Luna D, Coscojuela P, Maisterra O, Piñeiro S, Romero FJ, Alvarez-Sabin J, Molina CA. Extending the time window for endovascular procedures according to collateral pial circulation. Stroke. 2011;42:3465-3469. doi: 10.1161/STROKEAHA.111.623827.
137. Bang OY, Goyal M, Liebeskind DS. Collateral Circulation in Ischemic Stroke: Assessment Tools and Therapeutic Strategies. Stroke. 2015;46:3302-3309. doi: 10.1161/STROKEAHA.115.010508.
138. The ENOS Trial Investigators; Bath PM, Woodhouse L, Scutt P, et al. Effcacy of nitric oxide with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomized controlled trial. Lancet. 2015;385:617-628. doi: 10.1016/S0140-6736(14)61121-1.